Canfeng He1, Ruiting Lin1, Jing Zhang2, Lingling Sun2, Jietao Lin2, Lizhu Lin2. 1. The First Clinical Medical College, Guangzhou University of Chinese Medicine. 2. Department of Oncology Center, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Abstract
BACKGROUND: Acneiform eruptions from epidermal growth factor receptor tyrosine kinase inhibitors is a frequent adverse event in non-small cell lung cancer patients but the efficacy of its treatment including antibiotics, corticosteroid, sunscreen is still poorly understood. METHODS: Eight electronic databases (PubMed, EMBASE, ClinicalTrials.gov, etc) will be searched from inception to April 2020. Risk of bias of randomized controlled trials will be assessed in terms of the Risk of Bias 2 (RoB 2) tool. Eligible randomized controlled trials will be enrolled for a Bayesian network meta-analysis using R software. RESULTS: This study is still ongoing and the results will be submitted and published in a peer-reviewed scientific journal. CONCLUSION: We hope the results of this study will provide reliable evidence for the management of acneiform due to epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. ETHICS AND DISSEMINATION: Ethical approval is not applicable for this study is based on published trials. PROTOCOL REGISTRATION NUMBER: CRD42020206724.
BACKGROUND: Acneiform eruptions from epidermal growth factor receptor tyrosine kinase inhibitors is a frequent adverse event in non-small cell lung cancer patients but the efficacy of its treatment including antibiotics, corticosteroid, sunscreen is still poorly understood. METHODS: Eight electronic databases (PubMed, EMBASE, ClinicalTrials.gov, etc) will be searched from inception to April 2020. Risk of bias of randomized controlled trials will be assessed in terms of the Risk of Bias 2 (RoB 2) tool. Eligible randomized controlled trials will be enrolled for a Bayesian network meta-analysis using R software. RESULTS: This study is still ongoing and the results will be submitted and published in a peer-reviewed scientific journal. CONCLUSION: We hope the results of this study will provide reliable evidence for the management of acneiform due to epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. ETHICS AND DISSEMINATION: Ethical approval is not applicable for this study is based on published trials. PROTOCOL REGISTRATION NUMBER: CRD42020206724.
Authors: Antonio Passaro; Massimo Di Maio; Ester Del Signore; Bruno Gori; Filippo de Marinis Journal: Clin Lung Cancer Date: 2014-05-12 Impact factor: 4.785
Authors: Jonathan A C Sterne; Jelena Savović; Matthew J Page; Roy G Elbers; Natalie S Blencowe; Isabelle Boutron; Christopher J Cates; Hung-Yuan Cheng; Mark S Corbett; Sandra M Eldridge; Jonathan R Emberson; Miguel A Hernán; Sally Hopewell; Asbjørn Hróbjartsson; Daniela R Junqueira; Peter Jüni; Jamie J Kirkham; Toby Lasserson; Tianjing Li; Alexandra McAleenan; Barnaby C Reeves; Sasha Shepperd; Ian Shrier; Lesley A Stewart; Kate Tilling; Ian R White; Penny F Whiting; Julian P T Higgins Journal: BMJ Date: 2019-08-28
Authors: Aminah Jatoi; Abby Thrower; Jeff A Sloan; Patrick J Flynn; Nicole Lea Wentworth-Hartung; Shaker R Dakhil; Bassam I Mattar; Daniel A Nikcevich; Paul Novotny; Aleksandar Sekulic; Charles L Loprinzi Journal: Oncologist Date: 2010-08-26
Authors: Mario E Lacouture; Milan J Anadkat; René-Jean Bensadoun; Jane Bryce; Alexandre Chan; Joel B Epstein; Beth Eaby-Sandy; Barbara A Murphy Journal: Support Care Cancer Date: 2011-06-01 Impact factor: 3.603